Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Chemotherapy + Low-Dose Radiotherapy in Gastric/GEJ Adenocarcinoma
NCT07408609Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07408609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408609.